(Q39372450)

11 September 2017

Is abiraterone acetate well tolerated and effective in the treatment of castration-resistant prostate cancer? (English)

1 reference

11 September 2017

1 reference

ChEBI release 2020-05-28

ChEBI ID

68639

author name string

Emmanuel S Antonarakis

series ordinal

1

1 reference

PMCID

4014058

11 September 2017

Mario A Eisenberger

series ordinal

2

1 reference

11 September 2017

28 October 2008

1 reference

Nature Clinical Practice Oncology

11 September 2017

1 reference

11 September 2017

6

1 reference

11 September 2017

1

1 reference

11 September 2017

12-13

1 reference

Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.

11 September 2017

1 reference

PubMed Central

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4014058

Chemotherapy for hormone-refractory prostate cancer: now it's a question of "when?".

11 September 2017

1 reference

PubMed Central

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4014058

Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer

11 September 2017

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/18957947

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Increased metastatic lymph node 64 and CYP17 expression are associated with high stage prostate cancer

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/18957947

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NCPONC1262

1 reference

11 September 2017

1 reference

11 September 2017

1 reference

PMCID

4014058